Working… Menu
Trial record 8 of 93 for:    gemtuzumab ozogamicin

SCT Plus Immune Therapy in Average Risk AML/MDS

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02117297
Recruitment Status : Recruiting
First Posted : April 17, 2014
Last Update Posted : November 1, 2018
Information provided by (Responsible Party):
Mitchell Cairo, New York Medical College

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2021